IBB vs. HELX
IBB (iShares Nasdaq Biotechnology ETF) and HELX (Franklin Genomic Advancements ETF) are both Health & Biotech Equities funds. IBB is passively managed, while HELX is actively managed. Over the past 5 years, IBB returned 2.10%/yr vs -4.52%/yr for HELX. Their correlation of 0.86 suggests significant overlap in exposure. IBB charges 0.47%/yr vs 0.50%/yr for HELX.
Performance
IBB vs. HELX - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, IBB achieves a -0.68% return, which is significantly higher than HELX's -4.52% return.
IBB
- 1D
- 1.97%
- 1M
- -1.56%
- YTD
- -0.68%
- 6M
- -2.57%
- 1Y
- 34.50%
- 3Y*
- 9.40%
- 5Y*
- 2.10%
- 10Y*
- 6.23%
HELX
- 1D
- 1.03%
- 1M
- 2.06%
- YTD
- -4.52%
- 6M
- -7.35%
- 1Y
- 31.28%
- 3Y*
- 4.70%
- 5Y*
- -4.52%
- 10Y*
- —
IBB vs. HELX - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
IBB iShares Nasdaq Biotechnology ETF | -0.68% | 27.98% | -2.41% | 3.76% | -13.69% | 0.95% | 33.88% |
HELX Franklin Genomic Advancements ETF | -4.52% | 26.34% | -5.32% | 1.14% | -37.89% | 9.80% | 85.05% |
Correlation
The correlation between IBB and HELX is 0.86, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.86 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.89 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.89 |
Correlation (All Time) Calculated using the full available price history since Feb 28, 2020 | 0.86 |
The correlation between IBB and HELX has been stable across timeframes, ranging from 0.86 to 0.89 - a consistent structural relationship.
IBB vs. HELX - Sectors Allocation Comparison
Sectors
IBB
HELX
Healthcare
Basic Materials
-
Communication Services
-
-
Consumer Cyclical
-
-
Consumer Defensive
-
-
Energy
-
-
Financial Services
-
-
Industrials
-
-
Real Estate
-
-
Technology
-
Utilities
-
-
Healthcare
IBB
HELX
Basic Materials
IBB
-
HELX
Communication Services
IBB
-
HELX
-
Consumer Cyclical
IBB
-
HELX
-
Consumer Defensive
IBB
-
HELX
-
Energy
IBB
-
HELX
-
Financial Services
IBB
-
HELX
-
Industrials
IBB
-
HELX
-
Real Estate
IBB
-
HELX
-
Technology
IBB
-
HELX
Utilities
IBB
-
HELX
-
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
IBB vs. HELX — Risk / Return Rank
IBB
HELX
IBB vs. HELX - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for iShares Nasdaq Biotechnology ETF (IBB) and Franklin Genomic Advancements ETF (HELX). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| IBB | HELX | Difference | |
|---|---|---|---|
Sharpe ratioReturn per unit of total volatility | 1.74 | 1.51 | +0.24 |
Sortino ratioReturn per unit of downside risk | 2.50 | 2.18 | +0.33 |
Omega ratioGain probability vs. loss probability | 1.30 | 1.26 | +0.04 |
Calmar ratioReturn relative to maximum drawdown | 3.60 | 1.74 | +1.85 |
Martin ratioReturn relative to average drawdown | 11.43 | 4.52 | +6.91 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| IBB | HELX | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.74 | 1.51 | +0.24 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.10 | -0.19 | +0.28 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.27 | — | — |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.26 | 0.23 | +0.03 |
Drawdowns
IBB vs. HELX - Drawdown Comparison
The maximum IBB drawdown since its inception was -62.85%, which is greater than HELX's maximum drawdown of -58.75%. Use the drawdown chart below to compare losses from any high point for IBB and HELX.
Loading charts...
Drawdown Indicators
| IBB | HELX | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -62.85% | -58.75% | -4.10% |
Max Drawdown (1Y)Largest decline over 1 year | -9.63% | -18.01% | +8.38% |
Max Drawdown (3Y)Largest decline over 3 years | -24.85% | -29.48% | +4.63% |
Max Drawdown (5Y)Largest decline over 5 years | -39.82% | -58.75% | +18.93% |
Max Drawdown (10Y)Largest decline over 10 years | -39.82% | — | — |
Current DrawdownCurrent decline from peak | -5.64% | -40.09% | +34.45% |
Average DrawdownAverage peak-to-trough decline | -21.18% | -34.32% | +13.14% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 3.03% | 6.94% | -3.91% |
Volatility
IBB vs. HELX - Volatility Comparison
iShares Nasdaq Biotechnology ETF (IBB) and Franklin Genomic Advancements ETF (HELX) have volatilities of 6.86% and 6.88%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| IBB | HELX | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 6.86% | 6.88% | -0.02% |
Volatility (6M)Calculated over the trailing 6-month period | 15.38% | 16.18% | -0.80% |
Volatility (1Y)Calculated over the trailing 1-year period | 19.89% | 20.88% | -0.99% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 21.99% | 24.13% | -2.14% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.22% | 27.39% | -4.17% |
IBB vs. HELX - Expense Ratio Comparison
IBB has a 0.47% expense ratio, which is lower than HELX's 0.50% expense ratio.
Dividends
IBB vs. HELX - Dividend Comparison
IBB's dividend yield for the trailing twelve months is around 0.23%, less than HELX's 0.41% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
HELX Franklin Genomic Advancements ETF | 0.41% | 0.39% | 0.00% | 0.00% | 0.00% | 0.24% | 0.12% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
IBB iShares Nasdaq Biotechnology ETF | 0.23% | 0.23% | 0.29% | 0.26% | 0.31% | 0.21% | 0.21% | 0.33% | 0.20% | 0.30% | 0.19% | 0.03% |
Frequently Asked Questions
IBB and HELX have a correlation of 0.86, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
HELX has higher volatility (6.88%) compared to IBB (6.86%). In terms of maximum drawdown, IBB dropped -62.85% vs HELX's -58.75%.
On 5-year performance, IBB leads with 2.10% vs -4.52% for HELX. On fees, IBB is cheaper at 0.47% per year. Their volatility is very similar. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, IBB has performed better with a 2.10% return vs -4.52%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IBB is cheaper with a 0.47% expense ratio, compared with 0.50% for HELX.
HELX has the higher dividend yield at 0.41%, compared with 0.23% for IBB.
They also come from different issuers: iShares and Franklin Templeton. Their fees differ too: 0.47% for IBB and 0.50% for HELX.
IBB currently has the higher Sharpe Ratio (1.74 vs 1.51), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for IBB and HELX
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer